Gastroenterology

Emricasan Disappoints for Severe Portal HTN in NASH





(MedPage Today) -- Week 24 analysis of 48-week trial did not meet primary endpoint

Source link






Related posts

Fatty liver, cirrhosis double mortality risk in COVID-19

Newsemia

Gastric Parietal Cell Physiology And Helicobacter Pylori-Induced Disease

Newsemia

Use of 'High-Risk' Antibiotic Classes in Hospitals Tied to More C. Difficile Infections

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy